CRS Clinical Research Services’ Post

At the first JAMA Summit, a two-day meeting where stakeholders discussed how to better integrate clinical trials with clinical practice, officials from the FDA and summit participants highlighted the relationship between the randomized controlled trial (RCT), the downsides of RCTs, and the gap that exists in implementing trial results in clinical practice. https://lnkd.in/gqVYDvu5

Are you a patient, clinical trial investigator, clinical trial sponsor, or an ecosystem partner focusing on clinical trials in Alberta? Share your ideas on Health Canada's draft guidance for expanded access clinical trials! Let's shape the future of clinical trials together! 💡 #AlbertaClinicalResearch #ClinicalTrialsAlberta #AlbertaHealthResearch #clinicaltrials Clinical Trials Alberta Ryan Mercer Tammy Mah-Fraser

Are you running a Decentralised Clinical Trial? Almac is an industry leader in managing clinical trial supplies, for people at home, in places all over the world. Through Almac to Patient, sponsors have the ability to reach diverse patient populations and reduce the burden for people taking part in clinical trials. Find out how Almac can support your Decentralised Clinical Trial: https://hubs.li/Q02wFsxx0

🕵♀️ Did you know that a lot more information on ongoing clinical trials has been made publicly available in CTIS? With the change to the transparency rules, applicable as of Tuesday June 18th, you can now find information about many ongoing clinical trials that were previously deferred, such as: 🔵 Protocol and patient facing documents 🔵 Details on study design, as endpoints, objectives, and in- and exclusion criteria 🔵 Active sites and their contact information   If you have an ongoing clinical trial, make sure to check no confidential information has been published through the portal!

Are you running a Decentralised Clinical Trial? Almac is an industry leader in managing clinical trial supplies, for people at home, in places all over the world. Through Almac to Patient, sponsors have the ability to reach diverse patient populations and reduce the burden for people taking part in clinical trials. Find out how Almac can support your Decentralised Clinical Trial: https://hubs.li/Q02SjSm70

If you’re heading to DIA 2024, don’t miss IQVIA’s Barbara Arone and WEP Clinical’s Ana Tediosi as they discuss the complexities of Pre-Approval Access (PAA). Focusing on key decisions and success factors, this session will highlight pragmatic decisions that play into the development of efficient Pre-Approval Access programs, and address considerations and challenges for the provision of investigational products to patients outside of clinical trials. https://bit.ly/3yCE5cd #DIA2024

Phase IV clinical Trial overview

New on the Blog: Preparing for FDA-Mandated Diversity Action Plans (DAPs) in Clinical Trials As the FDA moves to ensure clinical trials better reflect diverse patient populations, sponsors face new requirements and opportunities for inclusive research. In our latest post, Suzanne Harris explains what you must know about preparing for DAPs to meet FDA expectations. Learn more: https://lnkd.in/e2QzAaNH

Join the Conversation! Attend Dynamic Global Events (DGE)'s 5th Clinical Trial Agreements tomorrow at 9:45! I'll be on a panel with Rachael Baker and Maureen Cawley. We'll discuss how the crucial role of CROs is undermined by potential miscommunications, and delays in budget negotiations. Learn strategies for efficient CRO involvement and explore common issues and solutions. Register today! Click below to register. #clinicaltrials #clinicalresearch #CRO

A clinical trial's effectiveness is highly dependent on the trial site's competence and resources and the Sponsor's level of support for the participating sites—Discover Minerva's expertise in overcoming clinical trial challenges. Our solutions redefine research excellence. Join us on the path to a healthier future. #MinervaResearchSolutions #regulatoryhurdles #TRIALTRIBULATIONS #crochallenges #TrialMonitoringIssues #qualitycontrolstruggles #MRS